companiesCompany
Ferring Pharmaceuticals
Ferring is the private Swiss pharma that brought the first bladder cancer gene therapy, Adstiladrin, to market.
Nadofaragene firadenovec (approved 2022, launched 2023-24 after manufacturing scale-up); reproductive and gastroenterology franchises.
ApprovedNon-replicating adenoviral gene therapy (intravesical)
Nadofaragene firadenovec · Adstiladrin
Nadofaragene firadenovec is the first gene therapy for bladder cancer: a virus that makes bladder cells produce interferon for weeks, given once every three months.
Not mapped hereGnRH antagonist depot
Degarelix · Firmagon
An injectable hormone blocker for prostate cancer that lowers testosterone within days without the initial surge caused by agonists.